Quality-first data labeling for model evaluation and training
Key people at Centaur.
Centaur was founded in 2017 by Zach Rausnitz (Founder) and Erik Duhaime (Founder) and Tom Gellatly (Founder).
Centaur was founded in 2017 by Zach Rausnitz (Founder) and Erik Duhaime (Founder) and Tom Gellatly (Founder).
Key people at Centaur.
Centaur Labs is a quality-first data labeling company specializing in medical and healthcare AI. It provides a platform that leverages a large network of over 58,000 healthcare experts to deliver accurate annotations across diverse biomedical data types such as text, 2D/3D imaging, video, audio, and waveform data. The company serves AI developers, medical device manufacturers, pharmaceutical companies, and research organizations by enabling them to build, monitor, and validate AI models at scale with high-quality labeled data. Centaur’s platform also supports customers who bring their own labelers and offers custom consulting for regulatory compliance, such as FDA approvals. The company has demonstrated strong growth momentum, publishing academic research, securing major deals, and expanding its technology capabilities with new APIs and validated dataset solutions[1][3][4].
Founded in 2017 by Erik Duhaime, Tom Gellatly, and Zach Rausnitz, Centaur Labs emerged from Duhaime’s PhD research and entrepreneurial activities at MIT. The idea originated from combining Duhaime’s wife’s study habits with his research on medical data annotation, leading to the creation of DiagnosUs, a gamified mobile app that incentivizes medical experts to label biomedical data accurately in exchange for small cash prizes. Early traction came through MIT’s Sandbox Innovation Fund and participation in the delta v startup accelerator, followed by acceptance into Y Combinator in 2018. The founders brought diverse backgrounds in software engineering, AI, and healthcare, which helped shape the company’s focus on expert-driven, scalable data labeling for medical AI[4][5].
Centaur Labs rides the wave of rapid AI adoption in healthcare, where high-quality labeled data is critical for training and validating AI models used in diagnostics, drug discovery, medical imaging, and regulatory submissions. The timing is favorable due to increasing investment in healthcare AI, growing regulatory scrutiny requiring rigorous validation, and the complexity of biomedical data that demands expert annotation. Centaur’s platform addresses the market need for scalable, accurate, and compliant data labeling, influencing the ecosystem by enabling faster AI development cycles and higher trust in AI outputs. Its approach also exemplifies the trend toward human-in-the-loop AI systems that combine machine efficiency with expert oversight[1][5].
Centaur Labs is poised to deepen its impact in healthcare AI by expanding partnerships, growing its sales and customer success teams, and penetrating new healthcare segments with rising AI investment. Future trends shaping its journey include increasing regulatory demands for AI validation, broader adoption of AI in clinical workflows, and the evolution of human-in-the-loop systems for ongoing model monitoring and improvement. Centaur’s influence is likely to grow as a critical infrastructure provider for trustworthy medical AI, moving beyond training to continuous feedback and validation throughout AI model lifecycles[1][5]. This positions Centaur as a key enabler of safe, effective, and scalable AI in healthcare, fulfilling its mission of quality-first data labeling.
